“ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.”
For more, click here.
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets
[From Pharma Times, August 15, 2018]